Navigation Links
Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
Date:7/9/2008

ld cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements, including, among others: our ability to obtain the capital required for research and operations, the inherent risks in early stage drug development including demonstrating efficacy, development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our Annual Information Form underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Lorus Therapeutics Inc.'s recent press releases are available through the Company's website at http://www.lorusthera.com. For Lorus' regulatory filings on SEDAR, pl
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
7. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014   MSC , ... patient safety, today announced the appointment of Mary ... With 28 years of experience preparing companies for ... 2013 as Executive Vice President of Corporate Development and ... performance improvement business , as well as corporate strategy ...
(Date:8/27/2014)... LOS ANGELES , Aug. 27, 2014  Lisa ... 30 years this July 4 holiday, thanks to a ... M.D., Ph.D., an internationally renowned clinician-researcher at the University ... is a 55-year-old Peoria, Ariz. ... progressively robs its victims of sight. On June 2, ...
(Date:8/27/2014)... 27, 2014 Flagship Biosciences LLC, a ... to the pharmaceutical and medical device industries, has announced ... fast growing company has consolidated its histology and tissue ... to Westminster, CO, just north of Denver. The ... W. 103rd Ave., Suite 100, Westminster, CO 80021 , ...
(Date:8/27/2014)... 27, 2014 Riviera Beach, Florida ... the creation of the Sancilio Scientific Advisory Board ... SCI’s philosophy of looking to nature for pharmaceutical ... actions are based on sound scientific data, analyses, ... Board provides a vehicle for SCI to receive ...
Breaking Biology Technology:MSC names Mary Beth Loesch President and CEO 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5Flagship Biosciences Announces Relocation and Expansion 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3
... A team of Arizona State University researchers will ... aid development of the next generations of lasers and ... in sensing and imaging for an array of defense ... by an Army Research Office grant through the defense ...
... 5 Signum Biosciences, Inc. today announced the appointment of Dr. ... Officer.  Dr. Shroot replaces Dr. Gregory Stock who will continue ... , , , ... Shroot brings to Signum an outstanding track record of success in ...
... the study at the Norris Comprehensive Cancer Center of the University ... , ... Inc. (TSX: AEZ; Nasdaq: AEZS ), (the "Company"), ... announced that the National Institutes of Health ("NIH") has awarded Dr. ...
Cached Biology Technology:Looking to leap forward on laser and photodetector technologies 2Signum Biosciences Names Braham Shroot as Chief Executive Officer 2Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108 2Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108 3Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108 4
(Date:8/27/2014)... have largely succeeded in sidelining the use of ... its potential contributions to Americans, health conditions. But ... best way to assuage the nation,s insatiable sweet ... & Engineering News (C&EN), the weekly news ... the article, Stephen Ritter, a senior correspondent at ...
(Date:8/27/2014)... associated with outcomes after the repair of peripheral ... mechanism of injury, nerve injured, injury location, defect ... repair materials. However, despite numerous studies of outcomes ... is no agreement regarding the independent predictors of ... the predictors has not been quantified. A study ...
(Date:8/27/2014)... As of seven hours ago the Happy Camp Complex ... Northern California, the July complex had consumed 35,530 as ... seventeen fires on the Happy Camp Ranger District of ... the area on August 11, 2014. All but three ... following is a list of contained fires and their ...
Breaking Biology News(10 mins):Happy Camp and July Fire Complexes in California 2
... Mich. School children who consume foods purchased in vending ... and that may be associated with being overweight, obese or ... coronary artery disease, according to research from the University of ... sold in school stores, snack bars and other related sales ...
... breakthroughs require 21st-century drug discovery tools, such as ... screening of effective, new compounds. That,s the theme ... held Sept. 11 on "Twenty-first Century Bioscience: In ... a variety of cutting-edge advances in the field ...
... 2, 2010⎯The old joke is a joke no more. In ... CBELife Sciences Education ( CBE-LSE ), the adage that ... laid to rest forever. "Bio-math" or "math-bio" is in the ... seven essays and 17 research articles on new ways to ...
Cached Biology News:Children who eat vended snack foods face chronic health problems, poor diet 2University at Buffalo symposium on in silico methods, high throughput screening 2University at Buffalo symposium on in silico methods, high throughput screening 3You say, 'bio-math,' I say, 'math-bio': Crossing science education divide 2
... ( Abpromise for all tested applications). ... conjugated to KLH derived from within residues ... 1.(Note: the amino acid sequence is proprietary)(Peptide ... Entrez GeneID: 1822 ...
An excellent carbonyl-reactive FRET quencher paired with Trp or Tyr. Minimum Purity: 95%. Abs(max): ~350 nm; Em(max): none. Solvent System:DMSO or DMF....
BI-1 Polyclonal Antibody Storage Temperature: -20C Shipping: gel pack Shelf-Life: 12 months...
RAW; Collected from 8-12 week old sexually mature mice that are free of common parasites; RAW Collected from 8-12 week old sexually mature mice that are free of common parasites....
Biology Products: